Effects of Maternal HIV Infection on Early Kaposi Sarcoma-Associated Herpesvirus Seroconversion in a Kenyan Mother-Infant Cohort.
HIV
KSHV seroconversion
Kaposi sarcoma-associated herpesvirus (KSHV)
Kenya
antibodies
children
mother-child pairs
oral shedding
pregnancy
transplacental antibody transfer
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
11 11 2023
11 11 2023
Historique:
received:
27
02
2023
accepted:
02
08
2023
pmc-release:
04
08
2024
medline:
14
11
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
We identified whether maternal human immunodeficiency virus (HIV) infection during pregnancy affects transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV)-specific antibodies and subsequent infant infection. We followed pregnant Kenyan women through delivery and their infants until age 2 years. Children were classified as HIV-exposed uninfected (HEU) or HIV-unexposed uninfected (HUU) based on maternal HIV status. Maternal venous and cord blood at delivery and child venous blood every 6 months were tested for antibodies to 20 KSHV antigens by multiplex bead-based immunoassay. Multiple comparisons were adjusted using false discovery rate (FDR). Maternal HIV infection was significantly associated with decreased transplacental transfer of antibodies against all KSHV antigens and lower cord blood levels for 8 antigens at FDR P < .10. Neither birth to 6-month antibody level changes nor 6-month levels differed in HEU and HUU, except for ORF50. By age 24 months, 74% of children KSHV seroconverted but HEU and HUU did not differ in time to seroconversion nor 2-year seropositivity after adjustment for child malaria infection. Maternal HIV infection reduced a child's initial KSHV antibody levels but did not affect age of infection. Regardless of HIV exposure in utero, KSHV seroconversion in Kenyan children occurred early; associated factors must be identified.
Sections du résumé
BACKGROUND
We identified whether maternal human immunodeficiency virus (HIV) infection during pregnancy affects transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV)-specific antibodies and subsequent infant infection.
METHODS
We followed pregnant Kenyan women through delivery and their infants until age 2 years. Children were classified as HIV-exposed uninfected (HEU) or HIV-unexposed uninfected (HUU) based on maternal HIV status. Maternal venous and cord blood at delivery and child venous blood every 6 months were tested for antibodies to 20 KSHV antigens by multiplex bead-based immunoassay. Multiple comparisons were adjusted using false discovery rate (FDR).
RESULTS
Maternal HIV infection was significantly associated with decreased transplacental transfer of antibodies against all KSHV antigens and lower cord blood levels for 8 antigens at FDR P < .10. Neither birth to 6-month antibody level changes nor 6-month levels differed in HEU and HUU, except for ORF50. By age 24 months, 74% of children KSHV seroconverted but HEU and HUU did not differ in time to seroconversion nor 2-year seropositivity after adjustment for child malaria infection.
CONCLUSIONS
Maternal HIV infection reduced a child's initial KSHV antibody levels but did not affect age of infection. Regardless of HIV exposure in utero, KSHV seroconversion in Kenyan children occurred early; associated factors must be identified.
Identifiants
pubmed: 37536370
pii: 7236812
doi: 10.1093/infdis/jiad310
pmc: PMC10640772
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1357-1366Subventions
Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI098511
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201500003I
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA239588
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA102667
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Matern Child Health J. 2015 Mar;19(3):606-14
pubmed: 24951129
J Infect Dis. 2017 Feb 1;215(3):415-419
pubmed: 27932617
J Infect Dis. 2018 Jan 4;217(2):263-269
pubmed: 29099933
J Oral Pathol Med. 2011 Jan;40(1):97-102
pubmed: 20969629
Rev Panam Salud Publica. 2016 Dec;40(6):401-409
pubmed: 28718488
J Infect Dis. 1996 May;173(5):1077-84
pubmed: 8627057
Trop Med Int Health. 2016 Jun;21(6):720-34
pubmed: 27091659
Int J Cancer. 2019 Nov 1;145(9):2468-2477
pubmed: 31265124
J Infect Dis. 2004 Aug 1;190(3):484-8
pubmed: 15243920
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):228-33
pubmed: 23403859
Am J Trop Med Hyg. 2022 Dec 19;108(2):394-402
pubmed: 36535249
J Infect Dis. 2004 Jun 15;189(12):2260-70
pubmed: 15181574
PLoS Pathog. 2014 Mar 27;10(3):e1004046
pubmed: 24675986
Clin Vaccine Immunol. 2015 Nov;22(11):1197-205
pubmed: 26376931
J Natl Cancer Inst. 2015 Jul 16;107(10):
pubmed: 26185193
J Infect Dis. 2021 Jul 15;224(2):303-311
pubmed: 33249494
Front Immunol. 2021 Mar 03;12:614246
pubmed: 33746958
Pediatrics. 2016 Apr;137(4):
pubmed: 27025960
Infect Agent Cancer. 2020 Nov 26;15(1):71
pubmed: 33292357
Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):300-8
pubmed: 24296855
Front Immunol. 2016 Aug 31;7:338
pubmed: 27630640
JAMA. 2011 Feb 9;305(6):576-84
pubmed: 21304083
Acta Paediatr. 1993 Dec;82(12):1034-8
pubmed: 8155920
AIDS. 2008 Feb 19;22(4):519-26
pubmed: 18301065
BMC Pediatr. 2015 Jun 06;15:66
pubmed: 26048411
J Infect Dis. 2015 Mar 15;211(6):1004-14
pubmed: 25271267
Clin Infect Dis. 2021 Feb 16;72(4):586-594
pubmed: 31974572
J Oral Microbiol. 2017 Oct 15;9(1):1384287
pubmed: 29081916
Int J Cancer. 2007 Jan 15;120(2):321-8
pubmed: 17066452
J Med Virol. 2014 Oct;86(10):1759-65
pubmed: 24692069
BMC Infect Dis. 2010 May 12;10:115
pubmed: 20462453
J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):351-5
pubmed: 17195763
J Infect Dis. 2011 Mar 1;203(5):625-34
pubmed: 21273188
J Clin Virol. 2017 Sep;94:50-56
pubmed: 28759772
J Infect Dis. 2016 Mar 15;213(6):985-91
pubmed: 26531246
Vaccine. 2015 Jan 29;33(5):621-7
pubmed: 25543061
Front Immunol. 2017 Oct 13;8:1294
pubmed: 29163461
Am J Epidemiol. 2008 Aug 1;168(3):311-20
pubmed: 18515794
BMJ. 2011 Mar 31;342:d1617
pubmed: 21454456
BMC Pediatr. 2021 Apr 19;21(1):183
pubmed: 33874900
J Infect Dis. 2017 Oct 17;216(7):842-849
pubmed: 28961804
J Infect Dis. 2003 Feb 15;187(4):559-68
pubmed: 12599072
Lancet Child Adolesc Health. 2020 Mar;4(3):220-231
pubmed: 31932246
Clin Vaccine Immunol. 2014 Dec;21(12):1661-7
pubmed: 25298109